Interestingly, a decrease in mean systolic blood pressure was observed as an effect of sermorelin treatment. However, as with the Corpas et al. study, no significant changes in testosterone levels were observed. This suggests that the timing and frequency of sermorelin treatment significantly affects IGF-1 levels, with a higher frequency of administration resulting in more significant IGF-1 increases. Essentially, sermorelin was found to augment the duration of rhythmic GH release without pushing serum levels above physiologic norms. Sermorelin therapy almost doubled the 12-h mean amount of GH released, but no significant changes to mean peak amplitude and number of peaks were observed. The older men had lower baseline IGF-1 levels when compared to the younger men but sermorelin treatment resulted in elevations in IGF-1 in a dose-response fashion to levels approaching those of the younger men. Measured outcomes included serum GH, IGF-1, IGFBP-3, and testosterone levels in addition to body weight, BMI, and waist-hip ratio. The widespread use of GH therapy as a performance-enhancing agent by multiple high-profile athletes further accelerated the implementation of these amendments (19). The 1988 and 1990 amendments to the Food, Drug and Cosmetic Act made it illegal to use GH in the United States for off-label conditions due to advertising that claimed GH can reverse the effects of aging. Side effects include joint stiffness, radiculopathy, edema, and a theoretical but never-demonstrated increased risk of malignancy. Although these findings offer promise to hypogonadal men struggling with weight loss despite adequate TTh, GH therapy remains controversial and is tightly regulated. This conversion then leads to a hyper-estrogenic state that inhibits luteinizing (LH) secretion, undermining intrinsic testicular health and stifling testosterone production (3). When combined with ipamorelin, MK-677 raises the floor while ipamorelin provides the pulse. However, somatostatin modulators are rarely used in research stacks because they risk disrupting the natural pulsatility that protects against receptor desensitization. Somatostatin is the endogenous peptide that inhibits GH release between pulses, ensuring GH secretion remains pulsatile rather than constant. Hexarelin is another potent secretagogue occasionally stacked with ipamorelin, though it carries the highest risk of desensitization. Typical protocols dose ipamorelin in the morning and GHRP-2 in the early afternoon, spaced 4–6 hours apart. The rationale for stacking within the same receptor class is half-life staggering. GHRP-2 and GHRP-6 are less selective than ipamorelin, meaning they activate additional pathways including cortisol and prolactin to varying degrees. I’ve been researching this compound for a while, and what I’ve found about its potential impact on bone health is worth sharing. Testosterone plays a significant role in bone metabolism, and while TRT can help maintain bone density, it doesn’t always reverse the clock. For men on TRT, bone density is actually something we should be paying close attention to. At standard bodybuilding doses where suppression occurs, they cross into the enhanced zone regardless of the marketing claims about selectivity. Low-dose SARMs at microdose levels, where bloodwork confirms no suppression, occupy a debatable edge of the natty plus zone. Enclomiphene, tongkat ali, fadogia agrestis, and other compounds that stimulate natural testosterone production without suppressing it occupy the natty plus zone. Once-daily dosing before sleep is the most common and effective schedule because it aligns with the body’s natural nocturnal GH surge. For fat-loss-specific research, pairing ipamorelin with tesamorelin is more mechanistically aligned. Serum IGF-1 elevation typically becomes measurable 4–6 weeks into a consistent ipamorelin stacking protocol, as hepatic IGF-1 synthesis lags behind acute GH pulses by 7–14 days. Ipamorelin stacking amplifies GH release by activating multiple receptor pathways simultaneously rather than relying on a single mechanism. A study in Endocrinology found that co-administration of a GHRP and a GHRH analog produced GH release 3–5 times higher than the sum of each peptide administered alone, a phenomenon called synergistic amplification. Activating multiple pathways simultaneously doesn't just add their effects. This means it won't cross-activate pathways that control appetite (a common side effect of GHRP-6), stress hormones, or glucose metabolism. Ipamorelin has high selectivity for GHS-R1a with minimal affinity for GHS-R1b or other ghrelin-related receptors. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that ipamorelin at 1 mcg/kg produced mean GH elevation of 2.7-fold over baseline, compared to 4.2-fold with GHRP-6 at equivalent doses. This hub is catered for ambitious biohackers who want personal control over their body. The muscle-building benefit is real but indirect — it comes from the entire cascade of improved recovery, sleep, and metabolic function. MK-677 stimulates your body’s own GH production in pulsatile patterns, which more closely mimics natural physiology. For Natty Plus practitioners using GH secretagogues like MK-677 rather than exogenous GH, the effects are even more nuanced. These are indirect but powerful contributors to muscle growth. Ascension Peptides carries ipamorelin at 5mg per vial, with third-party purity verification.
